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Abstract 
Background: Adding malaria vaccination to existing interventions could help to reduce the health burden due to 
malaria. This study modelled the potential public health impact of the RTS,S candidate malaria vaccine in 42 malaria‑
endemic countries in sub‑Saharan Africa.
Methods: An individual‑based Markov cohort model was constructed with three categories of malaria transmission 
intensity and six successive malaria immunity levels. The cycle time was 5 days. Vaccination was assumed to reduce 
the risk of infection, with no other effects. Vaccine efficacy was assumed to wane exponentially over time. Malaria 
incidence and vaccine efficacy data were taken from a Phase III trial of the RTS,S vaccine with 18 months of follow‑up 
(NCT00866619). The model was calibrated to reproduce the malaria incidence in the control arm of the trial in each 
transmission category and published age distribution data. Individual‑level heterogeneity in malaria exposure and 
vaccine protection was accounted for. Parameter uncertainty and variability were captured by using stochastic model 
transitions. The model followed a cohort from birth to 10 years of age without malaria vaccination, or with RTS,S 
malaria vaccination administered at age 6, 10 and 14 weeks or at age 6, 7‑and‑a‑half and 9 months. Median and 95 % 
confidence intervals were calculated for the number of clinical malaria cases, severe cases, malaria hospitalizations 
and malaria deaths expected to be averted by each vaccination strategy. Univariate sensitivity analysis was conducted 
by varying the values of key input parameters.
Results: Vaccination assuming the coverage of diphtheria‑tetanus‑pertussis (DTP3) at age 6, 10 and 14 weeks is 
estimated to avert over five million clinical malaria cases, 119,000 severe malaria cases, 98,600 malaria hospitaliza‑
tions and 31,000 malaria deaths in the 42 countries over the 10‑year period. Vaccination at age 6, 7‑and‑a‑half and 9 
months with 75 % of DTP3 coverage is estimated to avert almost 12.5 million clinical malaria cases, 250,000 severe 
malaria cases, 208,000 malaria hospitalizations and 65,400 malaria deaths in the 42 countries. Univariate sensitivity 
analysis indicated that for both vaccination strategies, the parameters with the largest impact on the malaria mortality 
estimates were waning of vaccine efficacy and malaria case‑fatality rate.
Conclusions: Addition of RTS,S malaria vaccination to existing malaria interventions is estimated to reduce substan‑
tially the incidence of clinical malaria, severe malaria, malaria hospitalizations and malaria deaths across 42 countries 
in sub‑Saharan Africa.
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Background
The health burden attributable to malaria is immense. 
The World Health Organization (WHO) estimated that 
in 2013 there were 163 million malaria cases and 528,000 
malaria deaths in the WHO Africa Region [1]. In the 
updated Global Burden of Disease study, malaria was 
the second leading cause of disability-adjusted life-years 
(DALYs) in sub-Saharan Africa and the first cause in 
western Africa in 2013 [2]. Most malaria deaths occur in 
children aged <5 years (estimated 437,000 malaria deaths 
in WHO Africa Region in 2013) [1]. Among children 
aged <5 years (excluding infants in the first month of life), 
malaria was the leading cause of death in Africa in 2010, 
accounting for 15 % of deaths [3].
Current preventive interventions in malaria aim to 
reduce malaria transmission by insect vectors (insec-
ticide spraying and the use of insecticide-treated bed 
nets), or to reduce the disease burden by prophylactic 
treatment of defined population groups such as pregnant 
women, infants or children [4, 5]. The main treatment 
for malaria is artemisinin-based combination therapy 
[6]. Decreases in estimated malaria case incidence (34 % 
decrease between 2000 and 2013) and estimated malaria 
mortality rate in children aged  <5 years (58  % decrease 
between 2000 and 2013) in the WHO Africa region 
have been reported, and probably reflect the combined 
effects of malaria intervention programmes, increased 
urbanization and overall economic development [1]. 
However, current malaria interventions have some 
limitations. Insecticide resistance has been reported in 
49/63 reporting countries worldwide since 2010, and 
artemisinin-resistant Plasmodium falciparum malaria 
has been reported in five countries in Southeast Asia [1]. 
Insecticide-treated nets need to be routinely distributed 
and replaced when they wear out in order to maintain 
coverage and therefore effectiveness. A slower growth 
in insecticide-treated bed net coverage in 2012–2013 in 
sub-Saharan Africa was associated with a slower decline 
in malaria mortality between 2011 and 2013 [1].
A malaria vaccine could be a valuable addition to exist-
ing malaria control interventions. The RTS,S malaria 
candidate vaccine is a pre-erythrocytic vaccine, directed 
against a protein from the sporozoite stage of the P. fal-
ciparum malaria parasite. It aims to trigger an immune 
defence to prevent the parasites infecting the liver and 
red blood cells. The RTS,S malaria candidate vaccine is 
administered in three doses given at one-month inter-
vals, with a possible booster dose given 18 months after 
the third dose. A double-blind randomized controlled 
Phase III trial in seven countries in Africa enrolled 
15,460 infants aged 6–12  weeks and children aged 
5–17  months between March 2009 and January 2011, 
and randomized them in a 1:1:1 ratio to receive the RTS,S 
candidate vaccine with a booster, without a booster, or 
a non-malaria comparator vaccine [7–9]. Results with 
18  months of follow-up from the third dose of vaccine 
were published in 2014, combining the first two groups 
and comparing them with the third (control) group [10]. 
In children, vaccination reduced clinical malaria cases 
by 46 % [95 % confidence interval (CI) 42, 50 %], severe 
malaria cases by 34  % (95  % CI 15, 48  %) and malaria 
hospitalizations by 41  % (95  % CI 30, 50  %). In infants, 
the reduction in clinical malaria cases was 27 % (95 % CI 
20, 32  %), with no significant protection against severe 
malaria or malaria hospitalization [10]. The highest num-
ber of malaria episodes averted was seen in areas with 
greatest malaria incidence [10].
The objective of the present analysis is to apply these 
18-month clinical trial results to estimate the poten-
tial public health impact of the RTS,S candidate malaria 
vaccine on the number of clinical malaria cases, severe 
malaria cases, hospitalizations and deaths in malaria-




The model is a static Markov cohort model with an indi-
vidual-based stochastic process following a birth cohort 
over 10 years. It includes three categories of malaria trans-
mission intensity, using definitions consistent with the 
Malaria Atlas Project (MAP) [11]. Low intensity is defined 
as parasite prevalence (PP) ≤5  %, moderate intensity as 
PP 5–40  %, and high intensity as PP  >  40  % in children 
2–10 years old. The structure of the model is shown in 
Fig. 1. At birth, individuals are either protected by mater-
nal antibodies (state M) or susceptible (state S). New-
borns protected by maternal antibodies gradually lose 
that immunity at a fixed rate (wm) to become susceptible. 
From a susceptible state they may be infected with malaria 
(state I). The transition probability for moving from state 
S to state I is the product of two parameters, a fixed prob-
ability of infection for each transmission category (q) 
and an age-dependent susceptibility factor (s). Infected 
individuals (state I) may have an asymptomatic episode 
with a probability (a) which depends on their immunity 
level or they may develop clinical symptoms (state C). 
A clinical episode may either be uncomplicated and be 
resolved, in which case individuals return to the suscep-
tible state (state S) with enhanced immunity, or lead to a 
severe episode (state F) in a fixed proportion which also 
depend on the level of immunity. A fixed proportion of 
severe episodes (state F) lead to death. The death state 
is not represented in the Figure, but it is included in the 
model. Six successive immunity levels after each infec-
tion (designated S1–S6, etc., in the Figure) are included in 
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the model. This means that for a higher level of immunity 
the probability for a new infection to cause a clinical epi-
sode and for a clinical episode to become severe are lower 
than for the previous stage of immunity. The number of 
immunity levels is limited but children may experience a 
larger number of infections. These additional infections 
would not improve natural immunity any more but for 
each infection a fixed proportion would result in a fully 
resistant state (state R). Although there is no sterilizing 
immunity to parasites, this model structure accounts for 
this resistant stage with full immunity against clinical epi-
sodes. This resistant state might be only a transient one, 
therefore a waning of naturally acquired immunity is 
tested with additional transitions from R to S6 and Si+1 to 
Si included in the calibration process.
Key assumptions include:
  • All episodes of clinical and severe malaria occurring 
in the trial were reported;
  • There are six levels of acquired immunity to clinical 
malaria depending on the previous number of infec-
tions;
  • A fixed percentage of severe infections result in 
death;
  • The effect of the vaccine is only to reduce the risk 
of infection, with no additional effect on the risk of 
developing clinical or severe disease;
  • Vaccine efficacy wanes over time by exponential 
decay;
  • No seasonality is included. Only one site (Nanoro in 
Burkina Faso) of the 11 trial sites exhibits a strongly 
seasonal pattern [10] which limits the availability of 
data to calibrate the model.
Incidence data
Each site in the Phase III trial was assigned to a transmis-
sion category using PP data from the Malaria Transmis-
sion Intensity (MTI) study, which was conducted at the 
same sites as the Phase III trial but in different children 
[12]. The incidence of clinical malaria in the control 
group at sites in each transmission category was obtained 
from the Phase III trial statistical report, and 95 % Chi-
square CI were derived using the method described by 
Ulm [13]. The secondary case definition 1 (malaria epi-
sode defined as a child presenting with fever  >37.5  °C 
and with P. falciparum parasites in the blood) was used 
because of the better sensitivity of this measure of 
malaria burden. The data are shown in Table 1.
Model calibration
The model was calibrated to reproduce simultaneously 
the incidence of malaria observed in the control arm of 
the Phase III trial for both age groups (infants and chil-
dren) in each transmission category and each six-month 
follow-up period, and the age distribution up to the 
age of 5 years in moderate and high transmission areas 
with no marked seasonality reported by Carneiro et  al. 
[14]. Since different definitions of transmission intensity 
M
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Fig. 1 Model structure. M maternal protection, S susceptible, I infected (parasites emerging from the liver), C clinical disease episode, F severe 
disease episode and there are 6 levels of immunity with compartments S, I, C and F divided into 6 levels, R resistant, wm waning of maternal immu‑
nity, q probability of infection, s susceptibility to infection as a function of age, a probability of asymptomatic infection, r recovery rate from clinical 
disease, w waning rate of acquired immunity, rimm probability of developing full immunity. The model assumes two processes for acquisition of 
immunity, one process that protects against clinical malaria of any severity and a faster process that protects against severe malaria
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categories were used, high transmission intensity data 
from the model were compared against moderate trans-
mission intensity data from Carneiro et  al., and moder-
ate transmission data from the model were compared 
against an average calculated from moderate and low 
transmission data from Carneiro et al. The age distribu-
tion in low transmission areas was not included because 
the definition of low transmission used by Carneiro et al. 
(PP  ≤  25  %) [14] was too different from the definition 
used in the model (PP ≤ 5 %).
This calibration of incidence to the observed data from 
the control arm of the trial was performed by fitting the 
following parameters (see Fig. 1):
  • Infection probability for each transmission category 
(q);
  • Probability of asymptomatic infection with each suc-
cessive infection (a1–a6);
  • Susceptibility factor (s) representing an increase in 
susceptibility with age to account for higher prob-
ability of mosquito bites with larger body surface, is 
derived from a negative exponential equation of the 
following type: 1 − exp(−k*n), where ‘n’ is the age of 
the child expressed as the number of model cycles (5 
days per cycle) and ‘k’ is derived by calibration;
  • Waning of immunity (w) implemented as a transition 
from Si+1 to Si;
  • Percentage of individuals gaining full immunity after 
six infections (rimm).
Calibration was performed by the least square method 
using Matlab (version R2013b) minimization tools (inte-
rior-point algorithm). To ensure that immunity always 
increased with successive infections, a constraint was set 
so that ai was always less than or equal to ai+1 for values 
of i from 1 to 5.
Capturing uncertainty and heterogeneity
A main source of uncertainty comes from the observa-
tion of incidence rates and vaccine efficacy estimates of 
the Phase III trial. Although the Phase III trial is powered 
for clinical malaria incidence and severe malaria inci-
dence overall, larger variations appear when stratifying 
data by malaria transmission level and periods of follow-
up. In order to capture this uncertainty, model parameter 
distributions are generated by repeating the calibration 
process with several incidence rates. These incidence 
rates are randomly drawn from a log-normal distribu-
tion generated using median values and 95 % CI for each 
6-month follow-up period and for each age-group.
This produced a set of values for the calibrated 
parameters from which non-parametric distribu-
tions were derived. A random value is drawn from the 
corresponding non-parametric distribution for each 
parameter to simulate the model process for one indi-
vidual. Table 2 shows the point estimates and CIs for the 
parameters. Additional file 1: Figure S1 shows the distri-
butions for q parameters and Additional file 2: Figure S2 
shows the distributions for parameters a1 to a6 and f1 to 
f6.
The distribution of the number malaria episodes per 
child in the Phase III trial in each transmission category 
indicated an individual-level heterogeneity in the risk of 
infection, as the proportion of children with no malaria 
episodes was higher in moderate and high transmission 
sites than would be expected with a homogeneous risk of 
infection. This heterogeneity in exposure was captured 
by assuming an individual-level variation around a mean 
exposure level corresponding to each of the three trans-
mission levels included in the model.
Severe malaria cases and hospitalizations
Data on the incidence of severe cases (defined as a para-
site density of  >5000) per 1000 person-years for each 
transmission category were obtained from the Phase III 
trial [10] (Table  1). A calibration step fitted the model 
parameters for the percentage of clinical cases becoming 
severe at each of the six modelled successive infections 
(f1–f6) to the incidence of severe cases observed in the 
Phase III trial. A constraint of diminishing percentages of 
clinical cases becoming severe with increasing number 
of previous infections (fi+1 < fi) is imposed to reflect the 
acquisition of immunity against severe malaria. This con-
straint results in a faster acquisition of immunity against 
severe disease than immunity against clinical disease.
The ratio of severe malaria cases to hospitalized 
malaria cases (defined as a parasite density of >5000 and 
excluding planned admissions and trauma) was calcu-
lated for each transmission category from the Phase III 
trial. However, the level of care available to patients in the 
Phase III trial was very high, with all malaria cases hav-
ing access to high levels of treatment resulting in very 
low malaria mortality. This is not representative of the 
real-life situation in sub-Saharan Africa, where not all 
malaria cases will have access to prompt treatment and/
or hospital care. Thus, compared with real-world situ-
ations, the Phase III trial would be expected to have a 
higher percentage of severe cases receiving hospital care, 
and a lower percentage of cases that become severe. The 
model thus required adjustment to reflect limited access 
to treatment for uncomplicated cases, and limited access 
to hospitalization for severe cases, as could be expected 
in real-life settings.
The proportion of cases in real-life settings with access 
to artemisinin-based combination treatment was taken 
from a published study for Ghana, Kenya and Tanzania 
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[15], with the average of these countries (fixed value of 
54 %) used for other countries. For the country-level esti-
mates, the percentage of severe cases that were hospital-
ized in real-life settings was assumed to be the same as 
the percentage with access to artemisinin-based combi-
nation treatment [15].
The risk of developing a severe episode from a treated 
uncomplicated episode was calibrated from the trial 
data as described above. The relative risk of developing a 
severe episode from an untreated uncomplicated episode 
was calculated using the following formula:
Severe malaria in population  =  (Proportion 
untreated × relative risk + proportion treated) × severe 
malaria in model
Proportion treated  =  Proportion of cases promptly 
treated with artemisinin-based combination therapy in 
various countries [16], and see also the associated online 
supplementary materials [17];
Severe malaria in model = Estimated incidence of severe 
malaria in children aged <5 years predicted by model;
Severe malaria in population  =  Incidence of severe 
malaria in hospitals in children aged 0–9 years [18], 
corrected for the proportion of severe episodes in chil-
dren aged <5 years using the age distribution from Car-
neiro et  al. [14] and for the proportion of severe cases 
who are not hospitalized [19].
This calculation was carried out for a range of countries 
in sub-Saharan Africa, and the mean relative risk across 
all the countries was 1.84 (95  % CI 1.68, 2.01). Table  3 
shows the values used for calculating severe malaria and 
hospitalizations.
Long‑term sequelae and deaths
The proportion of severe cases with long-term sequelae 
was calculated from published data on the proportion of 
severe cases that are categorized as cerebral malaria [20] 
and the percentage of cerebral malaria cases with seque-
lae [21]. The mean age of children presenting with cer-
ebral malaria is about 3 years compared to 1.8 for those 
presenting with malarial anaemia [21]. Malaria mortality 
was estimated as a fixed percentage of severe cases (case-
fatality rate), with values for hospitalized and non-hos-
pitalized severe cases obtained from Thwing et  al. [22] 
(Table 3).
Table 2 Point estimates, 95 % confidence intervals and distributions of fitted parameters
Parameter Point estimate 95 % CI Distribution
q, low transmission 1.88 e−3 1.224 e−3, 2.217 e−3 Non‑parametric
q, moderate transmission 30.50 e−3 19.222 e−3, 37.682 e−3 Non‑parametric
q, high transmission 184.8 e−3 87.972 e−3, 272.147 e−3 Non‑parametric
Probability of full immunity, rimm 1.97 % 1.93 %, 2.17 % Non‑parametric
Age‑related susceptibility factor, k 1.58 e−2 1.02 e−2, 3.63 e−2 Non‑parametric
Waning of acquired immunity, w 0
Probability of asymptomatic infection
 a1 8.57 % 0.29, 17.79 % Non‑parametric
 a2 38.49 % 7.74, 43.62 % Non‑parametric
 a3 38.58 % 7.94, 43.82 % Non‑parametric
 a4 38.68 % 8.37, 43.93 % Non‑parametric
 a5 38.90 % 15.65, 44.12 % Non‑parametric
 a6 54.19 % 25.87, 61.82 % Non‑parametric
Percentage of clinical cases that become severe with good access to care
 f1 2.40 % 1.19, 5,46 % Non‑parametric
 f2 2.13 % 1.19, 3.04 % Non‑parametric
 f3 2.13 % 1.19, 3.03 % Non‑parametric
 f4 2.05 % 1.19, 2.92 % Non‑parametric
 f5 1.99 % 1.19, 2.92 % Non‑parametric
 f6 1.33 % 0.96, 2.12 % Non‑parametric
Vaccine parameters
 Vaccine efficacy in infants aged 6–12 weeks 37.6 % 35.53, 41.11 % Log‑normal
 Half‑life in infants aged 6–12 weeks (months) 6.2 3.3, 11.7 Log‑normal
 Vaccine efficacy in children aged 5–17 months 58.2 % 56.5, 59.6 % Log‑normal
 Half‑life in children aged 5–17 months (months) 14.4 10.6, 19.2 Log‑normal
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Calibration of vaccine effect
The vaccine effect was modelled by applying a reduction 
in the force of infection (i.e., a reduction in the prob-
ability of moving from state S to state I in each succes-
sive infection). This type of vaccine effect was considered 
in order to reproduce the mechanism of action of RTS,S 
targeting the parasite at the pre-erythrocytic stage. It was 
assumed that vaccine efficacy would wane over time fol-
lowing an exponential decay function.
Point estimates and 95  % CI for vaccine efficacy were 
calculated from the Phase III clinical trial data for each 
of the three transmission categories and each of the two 
vaccination age groups using the exact Fisher formula 
[23].
The point estimates for the initial reduction in the force 
of infection post-dose 3 (or vaccine efficacy against infec-
tion) and decay parameter in the model were fitted to the 
vaccine efficacy observed in the Phase III trial simultane-
ously for each transmission level, each six-month follow-
up period and the entire 18-month follow-up period. 
The upper and lower bounds of the 95 % CI for vaccine 
efficacy against infection were obtained by fitting simul-
taneously the upper and lower values for each six-month 
follow-up period and the 18-month follow-up period. For 
the vaccine waning parameter, the upper (lower) bound 
was derived by combining the upper (lower) bound, 
point estimates and lower (upper) bound of vaccine effi-
cacy from the three successive six-month periods and 
the 18-month point estimate for vaccine efficacy. The 
fitted parameters for vaccine efficacy and the half-life of 
the waning function for each vaccination age group are 
shown in Table 2. Vaccine efficacy rates after one or two 
doses were set at fixed values and are shown in Table 3.
Estimation of country‑level impact
Estimates of the malaria burden in the absence of vacci-
nation and the potential impact of vaccination were made 
for 42 countries in sub-Saharan Africa. For each country, 
the size of the annual birth cohort and all-cause child 
mortality rates were taken from United Nations data [24, 
25]. The birth cohort was then allocated between the three 
transmission intensity categories using 2010 MAP data 
for that country [11]. In some countries a fraction of the 
birth cohort was considered not at risk or with an unsta-
ble risk of malaria. No impact of vaccination was con-
sidered in that population. The percentage of cases with 
access to treatment was taken from a published survey 
[15] for Ghana, Kenya and Tanzania and Demographic 
and Health and Malaria Surveys in 22 additional coun-
tries representing about 80 % of the birth cohorts of the 
42 countries. The average of 31 % access to anti-malarial 
treatment from the 25 countries in these surveys was used 
for remaining countries. The percentage of severe cases 
hospitalized and the case-fatality rate were set at fixed 
values for all countries (see Table 3). Running the model 
with these input data produced estimates of the numbers 
of clinical malaria cases, severe malaria cases, malaria 
hospitalizations and malaria deaths for each country. The 
proportion of the population in each malaria transmission 
category was assumed to remain stable over the projected 
period of 10 years. Data are presented in this paper for 
all 42 countries combined and for 8 individual countries: 
two countries with a large malaria burden (Democratic 
Republic of Congo and Nigeria accounting for 39  % of 
global malaria cases and 34 % of global malaria deaths [1]) 
and four of the countries in the Phase III trial (Burkina 
Faso, Ghana, Kenya, and Tanzania)  and two additional 
countries (Senegal and Uganda). Details for each country 
are presented in Additional file 3: Table S1.
Simulation process
The model cycle time was 5 days. For each transmission 
level, 50 stochastic simulations of a cohort of 10,000 indi-
viduals were conducted. For each simulation, parameter 
values for each of the 10,000 individuals in the cohort 
were randomly drawn from the distributions shown in 
Table  2. For the parameter q, which is the fixed prob-
ability of infection for each transmission category, there 
was also a second step to account for individual hetero-
geneity in exposure. After the value for q in the relevant 
transmission category (low, moderate or high) was drawn 
from the distribution, it was further adjusted for each 
individual in the cohort by a factor drawn from a uniform 
distribution ranging from 0 to 2 q. The model then fol-
lowed the cohort from birth to the age of 10 years, with 
one of the following interventions:
  • Without malaria vaccination;
  • With RTS,S malaria vaccination with doses given 
at age 6, 10 and 14 weeks (corresponding to the age 
group vaccinated at age 6–12 weeks in the trial, and 
to addition of the malaria vaccine to the Expanded 
Programme on Immunization (EPI) schedule), with 
coverage assumed to be the same as the diphtheria-
tetanus-pertussis (DTP3) vaccination coverage from 
each country;
  • With RTS,S malaria vaccination with doses given at 
age 6, 7-and-a-half and 9 months (corresponding to 
the age group vaccinated at age 5–17 months in the 
trial).
The vaccine efficacy in the 5–17  months age groups 
was used for children receiving the first dose at 6 months 
of age. Efficacy did not change between children receiv-
ing the first dose before or after 12  months of age. The 
coverage was assumed to reach 75 % of DTP3 vaccination 
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coverage from each country to account for the difficulty 
to reach children at a later age compared to DTP sched-
ule. The modelled outcomes were the numbers of clinical 
malaria cases, severe malaria cases, malaria hospitaliza-
tions and malaria deaths expected in the cohort from 
birth to the age of 10 years. This process was repeated 50 
times with and without vaccination and the values com-
pared to estimate the number of events averted by vacci-
nation for each outcome. At each year, the median value 
and the 2.5th and 97.5th percentile values (corresponding 
to the 95 % CI) were recorded for each event averted.
Sensitivity analysis
Univariate sensitivity analysis was conducted by running 
the model with different values for transmission, access 
to treatment, duration of vaccine protection, vaccine cov-
erage, risk of mortality in the community, relative risk of 
severe malaria for untreated cases, and case-fatality rate. 
The other parameters are held constant with median val-
ues provided in Tables 2 and 3.
An additional scenario analysis was conducted to com-
pare the model with estimates from the WHO World 
Malaria Report 2012 [26].
Results
Model calibration and validation
Figure 2 shows the incidence of clinical malaria over the 
18-month follow-up period observed in the control arm 
of the Phase III trial and estimated by the model, for each 
age group and each transmission level. The modelled 
results matched the trial results closely, although some 
differences appeared mainly in the infant age group for 
the low transmission category and in the older age group 
for moderate and high transmission. The model mostly 
underestimates the malaria incidence observed in the 
trial for the 5 to 17-month group.
Table 4 shows the number of clinical malaria cases and 
the percentage of severe malaria cases observed in the con-
trol and vaccine arms of the Phase III trial and predicted 
by the model. The modelled results matched well with the 
data (error in acceptable 10 % area) in the age group vac-
cinated at age 6–12 weeks although in the vaccine arm the 
model provided more severe cases than the trial (+23 %). 
In the age group vaccinated at 5–17 months the data were 
more difficult to reproduce because of the lower number 
of cases estimated in moderate and high transmission set-
tings. The model tended to underestimate the burden of 
malaria compared with the observed data from the trial in 
the 5–17 months as pointed out in Table 4.
The age distribution of malaria cases predicted by the 
model matched well with the age distribution published 
by Carneiro et  al. [14] for clinical cases (Fig.  3a) and 
severe cases (Fig. 3b).
Estimated public health impact of adding RTS,S 
vaccination to existing interventions
Figure  4 shows the estimated percentage of clinical 
malaria cases averted when adding RTS,S vaccination at 
age 6, 10 and 14  weeks and at age 6, 7-and-a-half and 
9 months in low, moderate and high transmission cat-
egories. Addition of RTS,S would be expected to reduce 
the incidence of clinical malaria in a higher propor-
tion for low transmission than higher transmission set-
tings. The benefit would be expected to occur in the first 
1–4 years, and the model predicted a small increase in 
later years in high transmission areas, reflecting delayed 
development of natural immunity. This appears in the 
reduction of proportion of events averted in children 
less than 10 years of age compared with children under 
5 years of age.
Fig. 2 Model validation, incidence of clinical malaria. Incidence of 
clinical malaria (defined as in Table 1) per child per year over the 
18‑month follow‑up period observed in the control arm of the Phase 
III trial and predicted by the model in each transmission category in a 
the 6–12 weeks age group and b the 5–17 months age group
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Estimated country‑level public health impact of adding 
RTS,S vaccination
Table  5 shows the estimated impact of adding RTS,S 
vaccination with doses administered at age 6, 10 and 
14  weeks or 6, 7-and-a-half and 9 months in 42 Afri-
can countries and eight specific countries (see Addi-
tional file  3: Table  S1 for results in each country). The 
estimates were based on vaccinating the birth cohort 
in 2017 and following them for 10 years, assuming no 
change in malaria transmission. Vaccination at age 6, 
10 and 14 weeks would be expected to avert almost five 
million cases of clinical malaria, 119,000 severe malaria 
cases, 98,600 malaria hospitalizations and 31,000 
malaria deaths. Vaccination at age 6, 7-and-a-half and 9 
months would be expected to avert almost 12.5 million 
cases of clinical malaria, 250,400 severe malaria cases, 
208,000 malaria hospitalizations and 65,400 malaria 
deaths. Therefore the higher efficacy obtained in five to 
17-months age group would overcome the lower cover-
age with vaccination starting at 6 months (75 % of DTP3).
Table  6 shows these estimated impact data expressed 
per 100,000 vaccinees. Countries with high malaria 
transmission, such as Nigeria and Burkina Faso, gener-
ally had higher values than countries with lower malaria 
transmission, such as Kenya. In Kenya more than 75 % of 
the population is not exposed or exposed to low levels of 
malaria transmission (i.e., with parasite prevalence below 
5 % in children of 2–10 years old) while 7 % would experi-
ence high malaria transmission (i.e., with parasite preva-
lence above 40 % in children of 2–10 years old). Exposure 
levels are also variable in Tanzania with about 45 % of the 
population in low transmission areas versus 12  % expe-
riencing high levels of transmission. This suggests that 
the projected impact of vaccination increases with trans-
mission even if the relative percentage of events averted 
is predicted to decrease with transmission. Vaccination 
at age 6, 7-and-a-half and 9 months generally resulted in 
higher values than vaccination at age 6, 10 and 14 weeks, 
reflecting the higher vaccine efficacy in the older age 
group.
Over the 42 African countries it is estimated that 2019 
(−3652; 6341) cases of neurological sequelae would be 
averted with vaccination at the age of 6, 10 and 14 weeks 
and 4258 (−7; 8191) cases of neurological sequelae with 
vaccination at the age of 6, 7-and-a-half and 9 months.
Sensitivity analysis
Figure  5a, b present the results of the univariate sen-
sitivity analysis for the total number of malaria deaths 
expected to be averted over 10 years by vaccination at age 
6, 10 and 14 weeks or vaccination at age 6, 7-and-a-half 
and 9 months, respectively. The parameters with the larg-
est impact on the results were waning of vaccine efficacy 
(decay) and the case-fatality rate.
Discussion
This analysis applied 18-month follow-up data from 
a Phase III clinical trial to estimate the potential pub-
lic health impact of the RTS,S candidate malaria vac-
cine in 42 malaria-endemic countries in sub-Saharan 
Africa using a cohort model. Two vaccination strate-
gies were considered, with doses administered either at 
6, 10 and 14 weeks (corresponding to adding the RTS,S 
vaccine to the EPI schedule) or at 6, 7-and-a-half and 9 
months. Each strategy was compared with no vaccina-
tion to estimate the expected impact of RTS,S vacci-
nation on averting clinical malaria cases, severe cases, 
malaria hospitalizations and malaria deaths in a birth 
cohort followed to the age of 10 years. Vaccination at age 
6, 10 and 14 weeks would be expected to avert over five 
million cases of clinical malaria, 119,000 severe malaria 
cases, 98,600 malaria hospitalizations and 31,000 malaria 
deaths. Vaccination at age 6, 7-and-a-half and 9 months 
would be expected to avert almost 12.5 million cases of 
clinical malaria, 250,000 severe malaria cases, 208,000 
malaria hospitalizations and 65,400 malaria deaths. The 
wide CIs reflect the combination of heterogeneity and 
uncertainty allowed for by the stochastic process in the 
model. The greatest uncertainty is around the impact on 
mortality.
After calibration, the model-predicted results closely 
matched the incidence of malaria observed in the con-
trol arm of the Phase III trial, and the published age 
Table 4 Model validation, clinical and  severe malaria 
in vaccine and control arms
Number of cases of clinical malaria (defined as in Table 1) over the 18-month 
follow-up period observed in the control and vaccine arms of the Phase III trial 
and predicted by the model in each age group
Twice as many patients were randomized to the vaccine arm as the control arm
Trial Model % 
Delta
Age group 6–12 weeks
 Clinical episodes
  Control 3718 3798 +2.2
  Vaccine 4487 4802 +7.0
 Severe episodes (% of clinical episodes)
  Control (%) 2.76 2.70 −2.2
  Vaccine (%) 2.91 3.58 +23
Age group 5–17 months
 Clinical episodes
  Control 5409 4967 −8.2
  Vaccine 5133 4154 −19
 Severe episodes (% of clinical episodes)
  Control (%) 2.20 1.96 −10.9
  Vaccine (%) 2.27 2.69 +18.5
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Fig. 3 Age distribution of clinical and severe malaria cases predicted by the model compared with published data. Comparison of the age distribu‑
tion of a clinical malaria cases and b severe malaria cases predicted by the model with age distribution data published by Carneiro et al. [14]. To 
allow for differences in transmission intensity definitions, the high transmission data from the model were compared with the moderate transmis‑
sion data from Carneiro et al., and for clinical cases the moderate transmission data from the model were compared against an average calculated 
from the moderate and low transmission data from Carneiro et al. Severe cases were compared against the hospitalized cases from Carneiro et al. 
for which data are not available for low transmission settings without seasonality. The Y axis shows the percentage of events occurring in a particu‑
lar month of age out of the total number of events during the observation period
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distribution of malaria cases [14]. However, when extrap-
olating at the country level, the modelled estimates for 
the number of clinical malaria cases and malaria deaths 
were larger than the estimates for 2010 in the WHO 
World Malaria Report 2012, which estimated the number 
of clinical malaria cases in the WHO Africa region in all 
age groups at 174 million (upper bound 242 million), and 
the number of malaria deaths at 596,000 (upper bound 
772,000) [26]. Possible reasons for the differences are
  • The model is calibrated to the incidence of clinical 
malaria in the control arm of the Phase III trial based 
on the secondary case definition (parasite density 
of >0 and presence of fever). It may be possible that 
the secondary case definition would have captured 
cases of fever due to other illnesses and the malaria 
parasites observed were present as a co-morbidity 
rather than the primary cause. The primary case 
definition (parasite density of >5000 and presence of 
fever) would be more specific and lead to a reduction 
of estimates by 35 %.
  • Estimated malaria episodes from WHO World 
Malaria report may not sufficiently adjust for under-
reporting, although a correction factor is used;
  • The model estimated malaria incidence based on 
reported proportion of children within categories 
of parasite prevalence from the MAP project. If this 
proportion varies over the year or the force of infec-
tion varies within a category, this is not captured by 
the model. Finally, the case-fatality rate for severe 
cases not treated in hospital is subject to a large 
uncertainty. An estimate from Thwing et  al. [22] is 
applied in the model but this factor has a large impact 
on malaria mortality estimates (see Fig. 5a, b).
However it should be noted that clinical vaccine effi-
cacy does not change with the primary or secondary case 
definition.
Another modelling estimate of 252 (95 % CI 171–353) 
million malaria episodes in sub-Saharan Africa for 2010 
has been reported by Griffin et al. [27]. These estimates 
include the total population and suggest the proportion 
of cases that are in under-fives varies from above 60  % 
at high transmission to below 20 %. Hay et al. [28] have 
reported estimates of 271 million of malaria cases due P. 
falciparum in Africa in 2007.
Obtaining a realistic estimate of the number of severe 
malaria cases and malaria hospitalizations is important 
as these outcomes contribute to understanding the health 
burden of malaria. However, available data are limited 
and generally relate to populations with access to treat-
ment. For example, the Phase III trial was conducted in 
settings where all patients had access to a high level of 
care. It was found that about half of the patients hospi-
talized with malaria met the case definition for severe 
malaria (parasite density  <5000), which is similar to 
the value reported in a study of hospitalized patients in 
Tanzania, where 4261 patients of the 9337 with positive 
blood slides had severe disease (46  %) [20]. However, 
neither of these studies could provide data on the frac-
tion of severe malaria cases that did not result in hospi-
talization, or on the risk of severe malaria developing in 
patients without access to treatment. The present analy-
sis attempted to adjust for limited access to prompt and 
high-quality treatment for uncomplicated cases and lim-
ited access to hospitalization for severe cases.
Fig. 4 Predicted percentage of clinical malaria cases averted with 
RTS,S vaccination at age 6, 10 and 14 weeks and at age 6, 7‑and‑a‑half 
and 9 months in children under 5 years of age (a) and in children 
under 10 years of age (b) for low (PP < 5 %), moderate (5 < PP < 40 %) 
and high transmission levels (PP > 40 %)
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Estimates of the potential impact of a pre-erythro-
cytic vaccine have been produced using other published 
malaria models developed by Imperial College London, 
the Swiss Tropical and Public Health Institute (Swiss 
TPH) and the Institute for Disease Modelling ([29–33]). 
These analyses have used a theoretical vaccine profile or 
calibrated the profile using results from a Phase II trial 
[29] and the 12-month follow-up data of the Phase III 
trial [31] of the RTS,S vaccine. Compared with the model 
presented in this study, the other models include the 
whole population (not just a birth cohort) and a dynamic 
malaria transmission process simulating vector popula-
tion infectiousness and its interaction with the human 
host population. Therefore, the entomological inocu-
lation rate is used as a measure of human host expo-
sure, and can be affected by other interventions, such 
as insecticide-treated nets and indoor residual spray-
ing. Those models include a mechanism of immunity 
acquisition acting on parasite density in individuals and 
reducing the probability of clinical disease, increasing 
tolerance to parasite and speeding-up parasite clearance. 
In the model described here, dynamic transmission is 
not included and no estimate for parasite density is made 
in individuals. Instead, parasite prevalence is used as a 
measure of exposure at the population level and a risk of 
infection is derived from trial incidence data. The immu-
nity acquisition process against clinical disease depends 
on the number of previous infections in the individual. 
Treatment of malaria episodes is the only other interven-
tion explicitly included in the model, because the effects 
of preventive vector-level interventions are assumed to 
be included in the estimates of parasite prevalence from 
MAP. Vaccine effect is introduced in a similar way to the 
other models, i.e., by reducing the initial risk of infection 
with no additional protection assumed. The definition of 
severe cases used in the present analysis is derived from 
the definition used in the Phase III trial, and differs from 
that used in an earlier analysis conducted with the Swiss 
TPH model [32]. However, the incidence of severe cases 
in the present analysis was similar to that reported by the 
Swiss TPH model [32].
One of the strengths of the present model is that it 
is simpler than the dynamic models and can be popu-
lated with readily available data, such as parasite preva-
lence and country-specific birth cohort data. The cohort 
approach used for the model helps to directly compare 
Table 6 Estimated country-level impact of RTS,S vaccination per 100,000 vaccinees
Estimated median and 95 % CIs for the numbers of clinical malaria cases, severe malaria cases, malaria hospitalizations and malaria deaths per 100,000 vaccinees 
averted by RTS,S vaccination with doses administered either at 6, 10 and 14 weeks or at 6, 7-and-a-half and 9 months
Outcomes are estimated for the annual birth cohort in each country, beginning in 2017 and following the cohort until the age of 10 years, assuming no change in 
malaria transmission
Country Median (95 % CI)
Clinical malaria  
cases averted
Severe malaria  
cases averted




Vaccination at 6, 10 and 14 weeks
 Burkina Faso 34,861 (310, 70,852) 621 (−1016, 2154) 516 (−844, 1789) 162 (−265, 562)
 Democratic Republic of Congo 27,132 (3581, 51,194) 640 (−1014, 1887) 532 (−843, 1567) 167 (−265, 493)
 Ghana 24,435 (2400, 46,521) 551 (−1098, 1610) 458 (−912, 1337) 144 (−287, 420)
 Kenya 6773 (845, 13,316) 197 (−424, 691) 164 (−353, 574) 51 (−111, 181)
 Nigeria 31,252 (2923, 60,259) 693 (−1133, 2124) 576 (−941, 1764) 181 (−296, 555)
 Tanzania 13,604 (1973, 25,448) 345 (−744, 1031) 287 (−618, 857) 90 (−194, 269)
 Senegal 7671 (1548, 14,331) 314 (−710, 1022) 261 (−590, 849) 82 (−185, 267)
 Uganda 28,104 (800, 56,058) 511 (−976, 1652) 425 (−811, 1372) 134 (−255, 431)
 42 countries in sub‑Saharan Africa 19,851 (1884, 38,413) 471 (−852, 1480) 391 (−708, 1229) 123 (−222, 386)
Vaccination at 6, 7.5 and 9 months
 Burkina Faso 115,124 (67,076, 137,011) 2042 (−11, 4048) 1697 (−9, 3363) 533 (−3, 1057)
 Democratic Republic of Congo 91,161 (59,510, 106,849) 1864 (82, 3499) 1549 (68, 2907) 487 (21, 914)
 Ghana 86,586 (59,758, 101,564) 1524 (15, 2857) 1267 (13, 2374) 398 (4, 746)
 Kenya 25,005 (18,192, 29,522) 542 (−61, 1100) 450 (−51, 914) 141 (−16, 287)
 Nigeria 104,755 (66,626, 123,236) 2078 (67, 3948) 1727 (56, 3280) 543 (17, 1031)
 Tanzania 50,152 (37,252, 58,652) 901 (−33, 1712) 748 (−27, 1422) 235 (−9, 447)
 Senegal 29,478 (23,357, 34,505) 796 (−92, 1580) 661 (−76, 1312) 208 (−24, 412)
 Uganda 96,898 (61,368, 114,643) 1555 (−7, 3012) 1292 (−6, 2502) 406 (−2, 787)
 42 countries in sub‑Saharan Africa 68,169 (45,007, 80,249) 1368 (−2, 2631) 1136 (−2, 2186) 357 (−1, 687)
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the results with the trial data. The model can thus be eas-
ily adapted and populated for specific countries. It is also 
relatively straightforward for decision-makers who are 
not experts in epidemiological modelling to understand 
and use. The present analysis has fitted the model to data 
from the most recent and large multicountry, multicentre 
trial on malaria vaccination, using the data available from 
the trial for the 18  months follow-up period, and may 
therefore be more representative of the current malaria 
epidemiological situation than models based on studies 
conducted during a period of very high transmission with 
no artemisinin-based combination therapy or long-last-
ing insecticide-treated nets.
The model has some limitations. First, as it is not a 
dynamic model it cannot take account of herd immunity. 
However, herd immunity is likely to be limited because 
of the small fraction of the population targeted by vac-
cination, the limited duration of protection and hence the 
small fraction of the parasite reservoir in human hosts 
which could be reached. Third, the model does not dis-
tinguish between different types of severe malaria, such 
as anaemia or cerebral malaria, which may have different 
implications for outcomes and resource use, although it 
does take account of the long-term neurological seque-
lae that can result from cerebral malaria. Fourth, it is 
assumed that the current levels of malaria transmission 
would remain stable over the period of analysis, although 
additional usage of long-lasting insecticide-treated nets 
and access to treatment are likely to further decrease 
malaria burden in the coming years. Conversely, the 
growing threat of resistance to insecticide and first-line 
treatment could lead to increasing malaria burden over 
that period.
A further area of work is to include seasonality in the 
model to improve the calibration using data from Nanoro 
trial site and impact estimate in seasonal settings, reflect-
ing factors such as changes in temperature and/or 
rainfall.
The uncertainty around impact estimates is larger for 
severe malaria events and malaria deaths due to the trial 
design and stochastic variability. This leads to having 
lower bounds below zero on impact estimates for these 
outcomes, although it is a marginal effect in the 6, 7-and-
a-half and 9 months schedule. It should be noted that the 
approach applied to characterize the uncertainty around 
the decay of vaccine-induced protection could potentially 
Fig. 5 a Univariate sensitivity analysis on vaccination at 6, 10 and 14 weeks. Effect of varying each indicated input parameter to the upper and 
lower values shown on the total number of malaria deaths expected to be averted over 10 years by vaccination at age 6, 10 and 14 weeks CT, 
artemisinin‑based combination therapy; CFR case‑fatality rate, DTP diphtheria‑tetanus‑pertussis, VE vaccine efficacy, MAP Malaria Atlas Project. b 
Univariate sensitivity analysis on vaccination at 6, 7‑and‑a‑half and 9 months. Effect of varying each indicated input parameter to the upper and 
lower values shown on the total number of malaria deaths expected to be averted over 10 years by vaccination at age 6, 7‑and‑a‑half and 9 months. 
ACT artemisinin‑based combination therapy, CFR case‑fatality rate, DTP diphtheria‑tetanus‑pertussis, VE vaccine efficacy, MAP Malaria Atlas Project
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lead to overestimation of its variability. Structural uncer-
tainty was assessed mainly around the natural immu-
nity acquisition mechanism. The calibration process 
has been performed for model structures involving less 
immunity stages showing poorer fit on age-distribution 
data and severe malaria events. To test more immunity 
stages a functional form of immunity acquisition should 
be assumed in order to limit the number of parameters. 
Alternatively, transitions for the waning of acquired 
immunity were included but did not improve the fit. 
Vaccination has a different mechanism of action than 
existing malaria interventions. Rather than targeting the 
vector or directly acting on parasites in the blood, vacci-
nation reduces the risk of infection by increasing immu-
nity to the malaria circumsporozoite protein. The use 
of interventions with complementary effects may allow 
greater malaria control than a single intervention alone.
Conclusions
Addition of RTS,S malaria vaccination to existing inter-
ventions with doses administered at either age 6, 10 and 
14 weeks, or at age 6, 7-and-a-half and 9 months, would 
be expected to reduce substantially the incidence of clini-
cal malaria, severe malaria, malaria hospitalizations and 
malaria deaths in children across 42 countries in sub-
Saharan Africa, compared with no vaccination. There is 
a larger uncertainty for the estimates impact on of severe 
malaria cases and deaths.
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